Published in Neurology on November 01, 1991
Temporal coincidence of myasthenia gravis and Guillain Barré syndrome associated with Hashimoto thyroiditis. Neurol Sci (2011) 0.86
Temporal coincidence between AMAN type of GBS and myasthenia gravis. J Neurol (2007) 0.76
Simultaneous Combined Myositis, Inflammatory Polyneuropathy, and Overlap Myasthenic Syndrome. Case Rep Neurol Med (2016) 0.75
Classification criteria for mild cognitive impairment: a population-based validation study. Neurology (2001) 3.92
Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study. Neurology (2007) 2.61
Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer's Disease. J Neurol Neurosurg Psychiatry (2006) 2.48
Cognitive frailty: rational and definition from an (I.A.N.A./I.A.G.G.) international consensus group. J Nutr Health Aging (2013) 2.44
Mild cognitive impairment: conceptual basis and current nosological status. Lancet (2000) 2.19
Report of the task force on designing clinical trials in early (predementia) AD. Neurology (2010) 1.75
CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions. J Neurol Neurosurg Psychiatry (2003) 1.69
Risk profiles for mild cognitive impairment and progression to dementia are gender specific. J Neurol Neurosurg Psychiatry (2008) 1.56
Epileptic electroencephalographic abnormalities and developmental dysphasias: a study of 32 patients. Brain Dev (1992) 1.49
Measuring cognitive change in subjects with prodromal Alzheimer's disease. J Neurol Neurosurg Psychiatry (2013) 1.48
Disability and mild cognitive impairment: a longitudinal population-based study. Int J Geriatr Psychiatry (2001) 1.43
Leisure activities and the risk of dementia in the elderly: results from the Three-City Study. Neurology (2009) 1.41
Effect of music therapy on anxiety and depression in patients with Alzheimer's type dementia: randomised, controlled study. Dement Geriatr Cogn Disord (2009) 1.05
Sleep organization and epilepsy. Epilepsy Res Suppl (1991) 1.04
Alzheimer's disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology. J Nutr Health Aging (2012) 1.00
Prediction of transition from cognitive impairment to senile dementia: a prospective, longitudinal study. Acta Psychiatr Scand (2003) 1.00
Effect of age on MSLT results in patients with narcolepsy-cataplexy. Neurology (2004) 1.00
Chiari malformation and sleep related breathing disorders. J Neurol Neurosurg Psychiatry (2007) 1.00
Development of screening guidelines and clinical criteria for predementia Alzheimer's disease. The DESCRIPA Study. Neuroepidemiology (2008) 1.00
A monozygotic twin pair discordant for narcolepsy and CSF hypocretin-1. Neurology (2004) 1.00
Recruitment strategies for preventive trials. The MAPT study (MultiDomain Alzheimer Preventive Trial). J Nutr Health Aging (2012) 0.95
Six and 18-month changes in mild to moderate Alzheimer's patients treated with acetylcholinesterase inhibitors: what can we learn for clinical outcomes of therapeutic trials? J Nutr Health Aging (2007) 0.94
[Recurrent hypersomnia]. Rev Neurol (Paris) (1988) 0.93
Diagnostic value of quantitative EEG in Alzheimer's disease. Neurophysiol Clin (2001) 0.93
Does education level determine the course of cognitive decline? Age Ageing (1996) 0.93
Changes in brain catecholamine levels in human cirrhotic hepatic encephalopathy. Gut (1980) 0.93
[Voice and speech disorders in the Parkinsonian syndrome]. Folia Phoniatr (Basel) (1975) 0.92
The effects of wine and tobacco consumption on cognitive performance in the elderly: a longitudinal study of relative risk. Int J Epidemiol (1999) 0.91
Influence on sleep of hyperthyroidism. Electroencephalogr Clin Neurophysiol (1967) 0.91
Depressive illness, depressive symptomatology and regional cerebral blood flow in elderly people with sub-clinical cognitive impairment. Age Ageing (1999) 0.91
Interhemispheric facilitation and inhibition studied in man with double magnetic stimulation. Electroencephalogr Clin Neurophysiol (1996) 0.90
Subclinical cognitive impairment: epidemiology and clinical characteristics. Compr Psychiatry (2000) 0.90
Heterogeneity in senile dementia of the Alzheimer type: individual differences, progressive deterioration or clinical sub-types? J Clin Epidemiol (1992) 0.89
["The 5 words": a simple and sensitive test for the diagnosis of Alzheimer's disease]. Presse Med (2002) 0.89
Cognitive decline in ageing: are AAMI and AACD distinct entities? Int J Geriatr Psychiatry (1999) 0.86
Progression of Alzheimer disease in Europe: data from the European ICTUS study. Curr Alzheimer Res (2012) 0.85
Cognitive impairment in motor neuron disease with bulbar onset. Amyotroph Lateral Scler Other Motor Neuron Disord (2001) 0.84
[Study of nocturnal sleep in chronic uremics subjected to an extrarenal purification]. Rev Neurol (Paris) (1967) 0.84
[Consensus statement on severe dementia]. Rev Neurol (Paris) (2005) 0.84
Conjugal amyotrophic lateral sclerosis: a report on two couples from southern France. Neurology (1994) 0.84
Correlations between cerebral blood flow variations and clinical parameters in temporal lobe epilepsy: an interictal study. J Neurol Neurosurg Psychiatry (1987) 0.84
Daytime sleep characteristics and their relationships with night sleep in the narcoleptic patient. Sleep (1986) 0.83
Consensus statement on dementia of Alzheimer type in the severe stage. J Nutr Health Aging (2005) 0.83
Very early onset AD with a de novo mutation in the presenilin 1 gene (Met 233 Leu). Neurology (2003) 0.83
[Somesthetic evoked potentials of the spinal cord and cervico-brachial neuralgia]. Rev Rhum Mal Osteoartic (1984) 0.83
Motor cortical dysfunction disclosed by single and double magnetic stimulation in patients with fibromyalgia. Clin Neurophysiol (2000) 0.83
The relationship between apolipoprotein E4 and lipid metabolism is impaired in Alzheimer's disease. Gerontology (2001) 0.83
[Somatosensory evoked potentials in amyotrophic lateral sclerosis and primary lateral sclerosis]. Rev Neurol (Paris) (1994) 0.83
[Electromyographic control of the effects of a muscle relaxant: LCB 29 in pyramidal hypertonia]. Rev Electroencephalogr Neurophysiol Clin (1976) 0.82
Biomarkers of Alzheimer's disease: the present and the future. Rev Neurol (Paris) (2013) 0.82
Regional cerebral blood flow during interictal state: differences between temporal lobe epilepsy and primary generalized epilepsy. Eur Neurol (1986) 0.82
[Clinical trial of isaxonine in alcoholic polyneuritis (author's transl)]. Nouv Presse Med (1982) 0.82
[Diminished regional cerebral blood flow during the intercritical period in temporal lobe epilepsy]. Rev Neurol (Paris) (1985) 0.82
A typology of sub-clinical senescent cognitive disorder. Br J Psychiatry (1996) 0.82
Motor evoked potentials (MEPs): evaluation of the different types of responses in amyotrophic lateral sclerosis and primary lateral sclerosis. Electromyogr Clin Neurophysiol (1996) 0.81
[HLA and amyotrophic lateral sclerosis (author's transl)]. Sem Hop (1979) 0.81
[Schwart-Jampel osteo-chondro-muscular dystrophy. 2 familial cases]. Arch Fr Pediatr (1975) 0.80
Myosin light chains in normal and pathological human skeletal muscles. Muscle Nerve (1983) 0.80
Prevention of progression to dementia in the elderly: rationale and proposal for a health-promoting memory consultation (an IANA Task Force). J Nutr Health Aging (2008) 0.80
Operational Definition of Active and Healthy Ageing (AHA): A Conceptual Framework. J Nutr Health Aging (2015) 0.80
No additional benefit of HRT on response to rivastigmine in menopausal women with AD. Neurology (2003) 0.79
Professional consensus on the treatment of agitation, aggressive behaviour, oppositional behaviour and psychotic disturbances in dementia. J Nutr Health Aging (2006) 0.79
[Anti-GAD antibodies in paraneoplastic cerebellar ataxia associated with limbic encephalitis and autonomic dysfunction]. Rev Neurol (Paris) (2012) 0.79
Reversal of symptomatic tumoral narcolepsy, with normalization of CSF hypocretin level. Neurology (2007) 0.79
[Regional cerebral blood flow in partial complex epilepsy with and without the presence of lesions]. Rev Electroencephalogr Neurophysiol Clin (1986) 0.78
[Effects of the association of sulbutiamine with an acetylcholinesterase inhibitor in early stage and moderate Alzheimer disease]. Encephale (2007) 0.78
Tau and apo E in CSF: potential aid for discriminating Alzheimer's disease from other dementias. Neuroreport (1999) 0.78
[Impact of music therapy on anxiety and depression for patients with Alzheimer's disease and on the burden felt by the main caregiver (feasibility study)]. Encephale (2008) 0.78
[Comparison of 6 different methods for lorazepam withdrawal. A controlled study, hydroxyzine versus placebo]. Encephale (1997) 0.78
Brain stem auditory-evoked potentials in the assessment of the transient ischemic attacks of the arterial vertebrobasilar system. Monogr Neural Sci (1984) 0.78
[Sleep in fibromyalgia: review of clinical and polysomnographic data]. Neurophysiol Clin (2001) 0.77
HLA-DR2 and narcolepsy. Sleep (1986) 0.77
Rapid cognitive decline in Alzheimer's disease. Consensus paper. J Nutr Health Aging (2008) 0.77
[Consensus statement of an interdisciplinary group of French experts on modalities of diagnosis and medical treatment of Alzheimer's disease at a treatable stage]. Rev Neurol (Paris) (1998) 0.77
[The influence of hyperthyroidism on sleep. Clinical and experimental study]. Rev Neurol (Paris) (1966) 0.77
[Sleep privation with eye movements using antidepressive agents]. Rev Neurol (Paris) (1972) 0.76
Characteristics of Alzheimer's disease patients with and without ApoE4 allele. Lancet (1996) 0.76
Short latency facilitation between pairs of threshold magnetic stimuli studied in amyotrophic lateral sclerosis. Neurophysiol Clin (2001) 0.76
Mild Alzheimer's disease: a "position paper". J Nutr Health Aging (2009) 0.76
Establishing the limits and characteristics of normal age-related cognitive decline. Rev Epidemiol Sante Publique (1997) 0.76
Analysing Time to Event Data in Dementia Prevention Trials: The Example of the GuidAge Study of EGb761®. J Nutr Health Aging (2015) 0.76
Normal latency values of early cortical somatosensory evoked potentials in children. Electroencephalogr Clin Neurophysiol (1987) 0.76
[Prenatal development of monoamine neurons in the rat]. C R Seances Soc Biol Fil (1976) 0.76
Neurodegenerative dementia and parkinsonism. J Nutr Health Aging (2010) 0.76
[Effects of zopiclone on sleep, daytime somnolence and nocturnal and daytime performance in healthy volunteers]. Neurophysiol Clin (1989) 0.76
Interictal regional cerebral blood flow during non specific activation test in partial epilepsy. J Neurol Neurosurg Psychiatry (1989) 0.76
[Brain stem auditory evoked potentials in "alcoholic epilepsy"]. Rev Electroencephalogr Neurophysiol Clin (1984) 0.75
[Temporal epilepsy and Ammon's horn discharges induced by oxygen deficiency anoxia]. Rev Neurol (Paris) (1967) 0.75
Post-anoxic myoclonic rhythmic discharges. Electroencephalogr Clin Neurophysiol (1968) 0.75
Temporal epilepsy and hippocampal discharges induced by oxyprivic anoxia. Electroencephalogr Clin Neurophysiol (1967) 0.75
Cerebellar protracted post-effects. Study of the cat released from its movements. Int J Neurol (1970) 0.75
[Night sleep in chronic uremics under extrarenal purification]. Electroencephalogr Clin Neurophysiol (1970) 0.75
[Evoked motor potentials obtained with double magnetic cortical stimulation: techniques and interpretation]. Neurophysiol Clin (1999) 0.75
[Cerebral repercussions of uremia]. Cah Med (1970) 0.75
[The development of monoamine neurons of the brain in the kitten]. C R Seances Soc Biol Fil (1970) 0.75